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Abstract: Adenosine monophosphate – activated kinase (AMPK) plays a key role in the coordination of the heart’s ana-
bolic and catabolic pathways. It induces a cellular cascade at the center of maintaining energy homeostasis in the cardio-
myocytes.. The activated AMPK is a heterotrimeric protein, separated into a catalytic  -  subunit (63kDa), a regulating  
- subunit (38kDa) and a  - subunit (38kDa), which is allosterically adjusted by adenosine triphosphate (ATP) and adeno-
sine monophosphate (AMP). The actual binding of AMP to the  – subunit is the step which activates AMPK.  
AMPK serves also as a protein kinase in several metabolic pathways of the heart, including cellular energy sensoring or 
cardiovascular protection. The AMPK cascade represents a sensitive system, activated by cellular stresses that deplete 
ATP and acts as an indicator of intracellular ATP/AMP.  In the context of cellular stressors (i.e. hypoxia, pressure over-
load, hypertrophy or ATP deficiency) the increasing levels of AMP promote allosteric activation and phosphorylation of 
AMPK. As the concentration of AMP begins to increase, ATP competitively inhibits further phosphorylation of AMPK. 
The increase of AMP may also be induced either from an iatrogenic emboli, percutaneous coronary intervention, or from 
atherosclerotic plaque rupture leading to an ischemia in the microcirculation. To modulate energy metabolism by phos-
phorylation and dephosphorylation is vital in terms of ATP usage, maintaining transmembrane transporters and preserving 
membrane potential.  
In this article, we review AMPK and its role as an important regulatory enzyme during periods of myocardial stress, regu-
lating energy metabolism, protein synthesis and cardiovascular protection. 
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INTRODUCTION 
  Adenosine monophosphate-activated kinase (AMPK) 
induces a cellular cascade at the center of maintaining energy 
homeostasis in the cell. AMPK received attention in 1973 
during a survey of the Acetyl-CoA-carboxylase (ACC) en-
zyme, an integral enzyme in fatty acid synthesis [1]. Carlson 
and Kim showed that ACC was regulated via phosphoryla-
tion and dephosphorylation [1, 2]. Specifically, Carlson de-
scribed AMPK as an enzyme which works as a function of 
the intracellular ATP/AMP quotient, which regulates ACC in 
response to energetic stress [1, 2].  
  The activated AMPK is a heterotrimeric protein, sepa-
rated into a catalytic  - subunit (63kDa), a regulating  - 
subunit (38kDa) and a  - subunit (38kDa), which is allos-
terically adjusted by adenosine triphosphate (ATP) and 
adenosine monophosphate (AMP) [2]. The actual binding of 
AMP to the -subunit activates AMPK. This process occurs 
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by three different pathways: (1) allosteric activation, (2) con-
formational changes and (3) inhibition of dephosphorylation 
(Fig. 1). In the second pathway, a conformational change in 
the - subunit by the -subunit facilitates the phosphorylation 
of the -subunit by an upstream AMPK kinases (AMPKK) 
e.g. serine/threonine kinase LKB1 and calmodulin-dependent 
protein kinase kinase (CaMKK) (Fig. 1). The third pathway, 
the inhibition of dephosphorylation, can occur by several 
protein phosphatases [2]. 
  AMPK serves as a protein kinase in several metabolic 
pathways of the heart, including cellular energy sensoring or 
cardiovascular protection [3-5] - previously examined in 
animal models [6-9]. In the context of cellular stressors (i.e. 
hypoxia, pressure overload, hypertrophy or ATP deficiency) 
the increasing levels of AMP promote allosteric activation 
and phosphorylation of AMPK [3-5]. On the other hand, 
increase of AMP may also be induced either from an iatro-
genic emboli, percutaneous coronary intervention, or from 
atherosclerotic plaque rupture leading to an ischemia in the 
microcirculation activates AMPK. This competitive inhibi-
tion may also be induced either from an iatrogenic emboli, 
percutaneous coronary intervention, or from atherosclerotic 
plaque rupture leading to an ischemia in the microcircula-338    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Heidrich et al. 
tion. To modulate energy metabolism by phosphorylation 
and dephosphorylation is vital in terms of ATP usage, main-
taining transmembrane transporters and preserving mem-
brane potential.  
  The exact role of AMPK in cardiac metabolism is highly 
controversial [4]. Calcium concentration plays a pivotal role 
in the contraction and relaxation of the myocardium. Cal-
cium-dependent ATPases are localized in the endoplasmatic 
reticulum (ER) and orchestrate the intracellular calcium con-
centration. As the calcium concentration rises, CaMKK acti-
vates AMPK by phosphorylation [10]. Highly regulated 
transporters prevent calcium unbalance which could lead to a 
mismatch between myocardial contractility and relaxation. In 
the acute phase of ischemia, AMPK inhibits anabolic me-
tabolism and ATP–consuming biosynthetic pathways and 
supports catabolic energy-generating pathways. However, 
AMPK chronically activated may inhibit overall energy me-
tabolism. This observation was first postulated by Dyck et 
al. and Carvajal et al. [4, 11],
 who reported the effects of 
AMPK in cardiac metabolism. The contrary effects could be 
described by the following: 
After the first adaption realized e.g. by saving ATP or 
raising glucose admission, some biosyntheses are strictly 
needful to preserve the cells life. On the other side the 
down regulation of AMPK leads to increase injury when 
the coronary blood flow is curbed. In general we could 
establish the hypothesis that AMPK works as a key stress 
signalling enzyme in heart or as a cellular energy sensor 
for cardiovascular protection [3, 4]. 
AMPK AND FATTY ACID METABOLISM  
  The heart uses various substrates for managing the en-
ergy metabolism, mainly fatty acids and pyruvate, 60-90 % 
and 10-40%, respectively [4]. Cardiomyocytes are able to 
switch between substrates for energy, either the oxidation 
fatty acids or glucose, depending on the different situations 
e.g. ischemia or anoxia. Thus, fatty acid metabolism is a sig-
nificant target for storing or creating energy for the heart. 
Therefore, AMPK modulates the metabolism of fatty acids in 
different ways. For example, AMPK phosphorylates the ace-
tyl-CoA carboxylase (ACC) at the amino acid sites Ser79, 
Ser1200 and Ser1215 [12, 13]. The phosphorylation and in-
hibition of ACC stimulates the transport of fatty acids into 
mitochondria, where the beta–oxidation is localized. Proc-
essing and consuming of fatty acids by cardiomyocytes re-
quires the carnitine-carrier-system (CCS). The CCS trans-
ports acyl-carnitine into the mitochondria and carnitine into 
the cytosol. The carnitine palmitoyltransferase (CTP–1), 
which synthesized acyl - carnitin, is regulated by malonyl-
CoA, the first product of fat acid biosynthesis (Fig. 2) [12-
14]. Allosteric regulation of CTP-1 by malonyl-CoA enables 
the biosynthesis of fatty acids.  
  Increasing the translocation of the lipoprotein lipase into 
the membrane subsequently increases the supply of fatty 
acids (Fig. 2). It is indispensible to segregate e.g. chylomi-
crons, triacylglycerides (TAGs), very low density lipopro-
teins (VLDLs) and low density lipoproteins (LDLs) into a 
single fatty acid. These individual fatty acids will channel 
into the beta-oxidation to generate reduced agent for acquire 
energy [13]. 
  Other targets of energy metabolism are the upstream fatty 
acid transporter (FAT/CD36) and the membrane associated 
fatty acid binding protein (FAPBpm), which are responsible 
for fatty acid uptake e.g. in the heart [3, 4]. Here, AMPK 
elevates the necessary protein expression to transport free 
fatty acids into cardiomyocytes (Fig. 2). The absence of 
AMPK results in a reduction of oxidation seen in cardio-
myocytes, thus cardiomyocytes rely on other substrates such 













Fig. (1). Schematic conformational change of AMPK during alteration of ATP/AMP-quotient enhance threonine172 phosphorylation. AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart  Current Cardiology Reviews, 2010, Vol. 6, No. 4    339 
centration of NADH/H
+ and FADH2 to extract ATP. 
NADH/H
+  and FADH2 work as reducing agents which are 
necessary to sustain the respiratory chain, located on the in-
ner mitochondrial membrane, with electrons. Generating 
ATP is essential for cardiomyocyte electrolyte balance and 
cellular protein volume. 
AMPK AND GLUCOSE METABOLISM 
  AMPK plays an important role in the metabolism of glu-
cose, producing the majority of ATP, second to the fatty acid 
oxidation in heart [16]. After AMP is activated, the levels of 
glucose uptake increase via either glucose transporter 4 
(GLUT 4) or up regulation of GLUT 1 by AMPK activation 
[3, 4, 16]. The targets of phosphorylation by AMPK and its 
mediators are very diverse, e.g. protein kinase C (PKC), p38 
mitogen-activated protein kinase or binding protein complex 
1. Each target is a central part in various signal transduction 
pathways, especially PKC and intracellular transports [9, 
26]. Glucose transporters are very connotative for glucose 
absorption and become translocated into cardiomyocyte’s 
cell membranes.  
  AMPK phosphorylates the 6-phosphofructo-2-kinase 
(PFK 2), a key enzyme of glucose depletion, to activate gly-






























Fig. (2). Fat acid metabolism. 
ACC   Acetyl-CoA  carboxylase 
FAPBpm   Fatty acid binding protein 
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anoxia [2, 5, 10, 14]. This activation is competitively regu-
lated. Fructose 2, 6 bisphosphate stimulates 6-phospho-
fructo-1-kinase (PFK 1), which is a celerity dependent step 
in glycolysis (Fig. 3). PFK 1 is an essential regulatory step in 
the glycolytic pathway.  
  The direct phosphorylation of glycogen-synthase and 
phosphorylase-kinase, each key enzymes of glycogen me-
tabolism, influences glycogen storage. Thus, AMPK induces 
a more efficient storage and utilization of glucose [16]. It is 
important to mention that the AMPK-mediated modulation 
of the above mentioned gene expression targets leads to car-
diac protection from anoxia and ischemia.  
AMPK IN HEART FAILURE 
  Hemodynamic disorders, for example oxidative stress or 
heart failure, either benefits, induces or instigates an inflam-
matory reaction [34]. The migration of macrophages, mono-
cytes and leukocytes and the expression of different pro-
inflammatory cytokines including TNF-, IL - 1, IL 6 are 
responsible for the systemic reactions [17, 18].  
  During an inflammatory reaction the activity of AMPK 
increases secondary to the release of MIF (macrophage mi-
gration inhibitory factor). Therefore MIF, a cytokine influ-
encing multiple aspect of systemic reactions during inflam-
mation, stimulates AMPK through CD74 [19]. In addition, 
MIF has the ability to modulate glucose uptake in hypoxic 
conditions. Given that, AMPK can regulate several pathways 
of energy metabolism in the heart during inflammation.  
  AMPK is involved in different pro-apoptotic (p53 pro-
tein, BAX, p38 MAPK) or anti-apoptotic pathways. During 
physical or chemical stress, AMPK activation is anti-
apoptotic [20]. During an acute lung injury, AMPK abates 
the pro-inflammatory reaction mediated by neutrophil granu-
locytes and therefore the extent of functional deficit [17]. 
During cellular stress such as hypoxia, the protein degrada-
tion process plays an important role in managing the intracel-
lular protein volume, another regulation target for AMPK. 
The increased incidence of autophage during myocardial 
ischemia shows a correlation with AMPK [21].  
  Several proteins (e.g. eEF-2K) or transcription factors 
(e.g. p27) stimulate AMPK and impair cardiomyocytes [22, 
23]. These metabolic pathways are seen in conditions such as 
myocardial ischemia and ischemia/reperfusion, demonstrat-
ing the important role of AMPK during ischemia compared 
to apoptosis or necrosis [22]. For example analogous to 
myocardial metabolism, during acute renal ischemia AMPK 
levels increase rapidly to orchestrate energy metabolism. The 
modulation of specific sodium transporters in kidney by 
AMPK is not well described [24].
 Inflammatory reactions are 
combined with high protein degradation and this signifies an 
enhanced performance of intracellular transport. Golgi appa-
ratus and endoplasmatic reticulum are in progress and in 
steadily rebuild. Alleviation ER-stress and therefore ER-
specific apoptotic pathways, by AMPK activation, protects 
cardiomyocytes from a hypoxic injury [25]. In summary, 
AMPK is involved in cellular apoptosis pathways and medi-
ates autophage activity during myocardial ischemia [22-25]. 
AMPK AND CARDIAC REMODELING 
  Cardiac ventricular hypertrophy is associated with up-
stream gene expression and subsequent changes in transcrip-
tion and translation, which result in an increase in cardiac 
myocyte volume. This increase in volume reflects the 
changes in response to physical and chemical alterations. 
Terai et al. described an increase of cardiac AMPK’s 1 and 
2 - subunits in chronic hypertrophied hearts [25]. LKB 1 
(tumor suppressor kinase), a serine/threonine kinase, modu-
lates AMPK to inhibit the m-target of rapamycin (mTOR) 



















GLUT Glucosetransporter AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart  Current Cardiology Reviews, 2010, Vol. 6, No. 4    341 
each down regulated and suppressed [3].
 mTOR signaling is 
involved in different parts of intracellular signal transduction 
e.g. gene transcription and gene translation or a central regu-
lation point of cell proliferation. 
  Various cell types, e.g. cardiomyocytes and extracellular 
matrix (ECM), are active in proliferation and differentiation 
as an adaption to changes in physiological conditions. Spe-
cifically, AMPK plays a central role in myocardial remodel-
ing by attenuating the growth and proliferation of cardiac 
fibroblasts. The extracellular signal-regulated kinase (ERK), 
which influences the growth and proliferation of cardiac fi-
broblasts, exhibits an interaction with AMPK [26-28].  
  The role of AMPK during periods of myocardial stress or 
cardiac hypertrophy, e.g. aortic constriction or hypertension, 
is highly controversial [4, 5, 11, 29-32].
 The exact steps nec-
essary for AMPK-regulated physiological hypertrophy is 
currently widely debated. However, without the diverse 
regulation of various targets by AMPK, cell death and ulti-
mately necrosis as seen in multiple cases of heart disease, 
occurs [5, 29-31, 33]. 
OUTLOOK 
  AMPK, with its multiple functional variations in the en-
ergy metabolism of the heart, owns a huge potential to treat 
cardiovascular diseases in several different ways [33]: e.g. it 
may reduce post-ischemic injury, can support surgical inter-
ventions or is even able to degrade risk factors, which lead to 
hemodynamic disorders [27, 34-36]. Therefore, in the future, 
AMPK may play a key role to approach metabolic dysfunc-
tions and will consequently improve the therapy of heart 
failure [36, 37]. 
SUMMARY 
  AMPK is an important regulatory enzyme during periods 
of myocardial stress, regulating energy metabolism, protein 
synthesis and cardiovascular protection. Once activated by 
the depletion of ATP, AMPK reversibly phosphorylates and 
dephosphorylates key enzymes in the heart’s energy metabo-
lism.  
  Thus, AMPK plays a key role in the coordination of the 
heart’s anabolic and catabolic pathways.  
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